<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01672801</url>
  </required_header>
  <id_info>
    <org_study_id>2012P-000186</org_study_id>
    <nct_id>NCT01672801</nct_id>
  </id_info>
  <brief_title>Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT</brief_title>
  <acronym>NIMO</acronym>
  <official_title>Using Nimodipine, a Calcium Channel Blocker, to Prevent LH Surge in Women Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: a Double-blinded, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston IVF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Village Fertility Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston IVF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to test the effectiveness of nimodipine in preventing a&#xD;
      luteinizing hormone (LH) surge in women undergoing ovulation induction with clomiphene&#xD;
      citrate. It is important to prevent the premature LH surge in controlled ovarian stimulation&#xD;
      to allow adequate recruitment of follicles, proper maturation of a dominant follicle before&#xD;
      ovulation, and effectively time insemination with semen to allow fertilization of a mature&#xD;
      egg to occur.&#xD;
&#xD;
      The investigators are also conducting this study to determine medication side effect profile&#xD;
      (including lightheadedness or dizziness from low blood pressure or rapid heart rate,&#xD;
      headache, and nausea), patient treatment compliance, and clinical pregnancy (positive&#xD;
      pregnancy test and ultrasound evidence of fetal heart rate). Finally, LH and follicle&#xD;
      stimulating hormone (FSH) serum levels will be measured to determine effect of nimodipine on&#xD;
      these hormones.&#xD;
&#xD;
      As a calcium channel blocker, nimodipine has been shown to block calcium mediated release of&#xD;
      gonadotropin releasing hormone in animal and preliminary human studies. The investigators&#xD;
      hypothesize that nimodipine, a calcium channel blocker, will prevent or delay the LH surge&#xD;
      during controlled ovarian stimulation cycles using clomiphene citrate in subfertile patients&#xD;
      undergoing assisted reproduction with intrauterine insemination (IUI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, subjects will be randomized to Placebo Comparator or Active Comparator. All&#xD;
      subjects will receive Clomid 100 mg for 5 days for the purpose of ovarian follicle&#xD;
      recruitment. Intervention will be initiated once ovarian follicle maturation has been&#xD;
      documented (≥1 ovarian follicle size of ≥ 17mm) and the absence of a premature LH surge has&#xD;
      been confirmed - this will be classified as intervention day 0. Subjects will receive their&#xD;
      assigned comparator (Placebo or Active) according the schedule below:&#xD;
&#xD;
        -  Intervention Day 0 - noon / afternoon / bedtime (3 doses)&#xD;
&#xD;
        -  Intervention Day 1 - morning / noon / afternoon / bedtime (4 doses)&#xD;
&#xD;
        -  Intervention Day 2 - morning (1 dose) Serum hormone levels and ultrasound examination&#xD;
           will occur on days 0,1 and 2 for all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH Surge</measure>
    <time_frame>7 days</time_frame>
    <description>Compare the change between placebo treated and nimodipine treated patients by the presence or absence of an LH surge on intervention Day 1 and Day 2. LH surge will be determined by serum LH levels at least two times the baseline serum LH (baseline serum LH = (cycle day 3 serum [LH] + cycle day 7 serum [LH])/2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Side Effects</measure>
    <time_frame>Starting day 0 of intervention to pregnancy test (approximately 15 days)</time_frame>
    <description>Medication side effect profile including: symptomatic hypotension (Note: vital signs will be recorded), symptomatic tachycardia (Note: vital signs will be recorded), headache, nausea. These will be self-reported with constructed questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gonadotropin Levels</measure>
    <time_frame>Intervention day 0 to ovulation (approximately 1-7 days)</time_frame>
    <description>Calculated changes in serum LH, FSH, and estradiol levels between patients in nimodipine and placebo arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Unexplained Infertility</condition>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Anovulatory</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <other_name>Nimotop</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 25-40 years at the time of enrollment&#xD;
&#xD;
          -  Both ovaries intact by history and ultrasound assessment&#xD;
&#xD;
          -  Early follicular phase (day 2-4) serum FSH level &lt;20 mIU/mL&#xD;
&#xD;
          -  Diagnosis of subfertility with a recommended treatment of COH and IUI&#xD;
&#xD;
          -  Providing written informed consent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt;38 kg/m2&#xD;
&#xD;
          -  Early follicular phase (day 2-4) serum FSH level ≥20 mIU/mL&#xD;
&#xD;
          -  History of overstimulated cycle defined as &gt;3 mature follicles of ≥17 mm&#xD;
&#xD;
          -  Abnormal uterine cavity and/or tubal disease (as evidenced by sonohysterogram or&#xD;
             hysterosalpingogram)&#xD;
&#xD;
          -  Diagnosis of infertility with a clear indication for in-vitro fertilization, such as&#xD;
             bilateral tubal occlusion&#xD;
&#xD;
          -  Severe male factor infertility: Total Motile Sperm Count &lt; 2x106 post washing (sperm&#xD;
             deemed inadequate for IUI preparation)&#xD;
&#xD;
          -  Any ovarian or abdominal abnormality that may interfere with adequate TV ultrasound&#xD;
             evaluation&#xD;
&#xD;
          -  Absence of one or both ovaries&#xD;
&#xD;
          -  Any contraindication to being pregnant or carrying a pregnancy to term&#xD;
&#xD;
          -  Unexplained gynecological bleeding&#xD;
&#xD;
          -  Any medical condition that would jeopardize the patient or the integrity of the data&#xD;
             obtained including:&#xD;
&#xD;
          -  Prior reaction or side effects from previous calcium channel blocker use&#xD;
&#xD;
          -  Any medical condition that may interfere with the absorption, distribution, metabolism&#xD;
             or excretion of nimodipine such as hepatic disease, hypertension, seizure, concurrent&#xD;
             infection, depression, reflux (see #12 below).&#xD;
&#xD;
          -  Mental health status resulting in cognitive or emotional impairment that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  The concurrent use of any of the following drugs: [These medications have been shown&#xD;
             to effect the availability of the medication or worsen hypotension symptoms]&#xD;
&#xD;
          -  Antihypertensives (eg. ACE inhibitors, alpha-adrenergic blocking agents,methyldopa,&#xD;
             beta-blockers, diuretics, PDE5 inhibitors, and other calcium antagonists)&#xD;
&#xD;
          -  Antiepileptics (eg. phenobarbital, phenytoin, carbamazepine or valproic acid)&#xD;
&#xD;
          -  Macrolide antibiotics (eg, erythromycin)&#xD;
&#xD;
          -  Azole antimycotics (eg, ketoconazole)&#xD;
&#xD;
          -  HIV protease inhibitors (eg, ritonavir)&#xD;
&#xD;
          -  Antidepressants (eg, nefazodone and fluoxetine)&#xD;
&#xD;
          -  Cimetidine&#xD;
&#xD;
          -  Patient unable to communicate adequately with the investigators and to comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  Unwillingness to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S Penzias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center / Boston IVF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston IVF</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chen EC, Javors MA, Norris C, Siler-Khodr T, Schenken RS, King TS. Dependence of 3',5'-cyclic adenosine monophosphate--stimulated gonadotropin-releasing hormone release on intracellular calcium levels and L-type calcium channels in superfused GT1-7 neurons. J Soc Gynecol Investig. 2004 Sep;11(6):393-8.</citation>
    <PMID>15350253</PMID>
  </reference>
  <reference>
    <citation>Krsmanović LZ, Stojilković SS, Merelli F, Dufour SM, Virmani MA, Catt KJ. Calcium signaling and episodic secretion of gonadotropin-releasing hormone in hypothalamic neurons. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8462-6.</citation>
    <PMID>1326758</PMID>
  </reference>
  <reference>
    <citation>Núñez L, Villalobos C, Boockfor FR, Frawley LS. The relationship between pulsatile secretion and calcium dynamics in single, living gonadotropin-releasing hormone neurons. Endocrinology. 2000 Jun;141(6):2012-7.</citation>
    <PMID>10830284</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>August 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2012</study_first_posted>
  <results_first_submitted>July 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston IVF</investigator_affiliation>
    <investigator_full_name>Alan Penzias</investigator_full_name>
    <investigator_title>Associate Professor of Obstetrics, Gynecology and Reproductive Biology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes&#xD;
Placebo: oral administration</description>
        </group>
        <group group_id="P2">
          <title>Nimodipine</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes&#xD;
Nimodipine: oral administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes&#xD;
Placebo: oral administration</description>
        </group>
        <group group_id="B2">
          <title>Nimodipine</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes&#xD;
Nimodipine: oral administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="31" upper_limit="36"/>
                    <measurement group_id="B2" value="37" lower_limit="31" upper_limit="42"/>
                    <measurement group_id="B3" value="35" lower_limit="31" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LH Surge</title>
        <description>Compare the change between placebo treated and nimodipine treated patients by the presence or absence of an LH surge on intervention Day 1 and Day 2. LH surge will be determined by serum LH levels at least two times the baseline serum LH (baseline serum LH = (cycle day 3 serum [LH] + cycle day 7 serum [LH])/2).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes&#xD;
Placebo: oral administration</description>
          </group>
          <group group_id="O2">
            <title>Nimodipine</title>
            <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes&#xD;
Nimodipine: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>LH Surge</title>
          <description>Compare the change between placebo treated and nimodipine treated patients by the presence or absence of an LH surge on intervention Day 1 and Day 2. LH surge will be determined by serum LH levels at least two times the baseline serum LH (baseline serum LH = (cycle day 3 serum [LH] + cycle day 7 serum [LH])/2).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Side Effects</title>
        <description>Medication side effect profile including: symptomatic hypotension (Note: vital signs will be recorded), symptomatic tachycardia (Note: vital signs will be recorded), headache, nausea. These will be self-reported with constructed questionnaire.</description>
        <time_frame>Starting day 0 of intervention to pregnancy test (approximately 15 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes&#xD;
Placebo: oral administration</description>
          </group>
          <group group_id="O2">
            <title>Nimodipine</title>
            <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes&#xD;
Nimodipine: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Side Effects</title>
          <description>Medication side effect profile including: symptomatic hypotension (Note: vital signs will be recorded), symptomatic tachycardia (Note: vital signs will be recorded), headache, nausea. These will be self-reported with constructed questionnaire.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gonadotropin Levels</title>
        <description>Calculated changes in serum LH, FSH, and estradiol levels between patients in nimodipine and placebo arms</description>
        <time_frame>Intervention day 0 to ovulation (approximately 1-7 days)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes&#xD;
Placebo: oral administration</description>
        </group>
        <group group_id="E2">
          <title>Nimodipine</title>
          <description>All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes&#xD;
Nimodipine: oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Penzias</name_or_title>
      <organization>Boston IVF</organization>
      <phone>781-434-6500</phone>
      <email>apenzias@bostonivf.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

